A Clinical Management of Bronchial asthama
Phase 2
- Conditions
- Health Condition 1: null- Intermittent fever, wheezing, lack of appetite
- Registration Number
- CTRI/2014/08/004825
- Lead Sponsor
- ational Institute of Siddha
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Intermittent fever
Wheezing
Insomnia
Hiccough
Lack of appetite
Dyspnoea
Indrawing of respiratory muscles
Exclusion Criteria
Jaundice
Enteric fever
Pneumonia
Congenital heart disease
Any other serious illness
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Results and observation during the study inclusive of clinical improvementsTimepoint: 2-3 months
- Secondary Outcome Measures
Name Time Method Results and observation during the study inclusive of clinical improvementsTimepoint: Before treatment and after treatment
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does Kodagasalai Ennai target in Suzhimantham treatment for children with bronchial asthma?
How does Kodagasalai Ennai compare to standard-of-care bronchodilators and anti-inflammatory agents in pediatric asthma management?
Are there specific biomarkers associated with Suzhimantham that predict treatment response to Kodagasalai Ennai in children?
What are the potential adverse events and safety management strategies for Kodagasalai Ennai in pediatric asthma trials?
What related compounds or combination therapies are being explored for Suzhimantham in bronchial asthma alongside Kodagasalai Ennai?